Rituximab Biosimilar
Non-Hodgkin Lymphoma, Rheumatoid Arthritis
Key Facts
About Dr. Reddy's Laboratories
Founded in 1984, Dr. Reddy's Laboratories has evolved from an API manufacturer into a global pharmaceutical leader with a mission to accelerate access to affordable and innovative medicines. Its core strategy balances a robust generics and biosimilars business with targeted investments in complex generics, innovative therapies, and strategic partnerships. Key recent achievements include the first-to-market launch of a generic semaglutide injection in India, expansion of its biosimilar portfolio in developed markets, and a stated goal to touch 1.5 billion patient lives by 2030.
View full company profileAbout Eurofarma Laboratórios
A leading Brazilian pharmaceutical company specializing in generics, branded drugs, and hospital products for Latin American markets.
View full company profileAbout Bio Usawa Biotechnology
African biotech building low‑cost monoclonal antibody biosimilars to expand cancer treatment access.
View full company profileAbout Laboratorio Elea Phoenix
Argentina‑based pharma firm providing a wide range of generic APIs and finished products for global markets.
View full company profile